Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Apr 04, 2025

  • Pharmaceuticals
  • R&D

Roche’s Announcement Regarding Trontinemab (Presentation of Latest Data in Alzheimer’s Disease at AD/PD)

TOKYO, April 4, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on April 3, including information on latest data of trontinemab for Alzheimer’s disease, presented at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders.

Please refer to the link below for details of the Roche’s press release:
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
https://www.roche.com/media/releases/med-cor-2025-04-03

[PDF 247KB]

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp

Back